Abstract
Sleep disorders have been shown to increase the risk of dementia. This particular aspect may affect the cognition of the patient, leading to behavioral disorders and depression. In early symptomatic Alzheimer’s Disease (AD), Default Mode Network (DMN) disruption occurs and progresses along with the course of the disease. This review mainly focuses on the leading causes of AD along with management of conditions like insomnia, obstructive sleep apnea, night-time sleep duration, Circadian Rhythm Disorder (CRD), neuroendocrine alternation, and impaired sleep to prevent the use of drugs that can cause complications, especially falls or additional cognitive deficits. Moreover, this study highlights the identification of molecular mechanisms like the effect of impaired sleep on amyloid β (Aβ) and tau dynamics, impaired proteostasis, along with appropriate measures to treat few contributing factors that lead to insomnia in AD or Mild Cognitive Impairment (MCI).
Keywords: Alzheimer's disease, dementia, impaired sleep, insomnia, cognitive impairment, sleep disturbance.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance
Volume: 20 Issue: 7
Author(s): Pallavi Singh Chauhan, Meerambika Mishra, Bhupendra Koul, Mayank Sharma and Dhananjay Yadav*
Affiliation:
- Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541,South Korea
Keywords: Alzheimer's disease, dementia, impaired sleep, insomnia, cognitive impairment, sleep disturbance.
Abstract: Sleep disorders have been shown to increase the risk of dementia. This particular aspect may affect the cognition of the patient, leading to behavioral disorders and depression. In early symptomatic Alzheimer’s Disease (AD), Default Mode Network (DMN) disruption occurs and progresses along with the course of the disease. This review mainly focuses on the leading causes of AD along with management of conditions like insomnia, obstructive sleep apnea, night-time sleep duration, Circadian Rhythm Disorder (CRD), neuroendocrine alternation, and impaired sleep to prevent the use of drugs that can cause complications, especially falls or additional cognitive deficits. Moreover, this study highlights the identification of molecular mechanisms like the effect of impaired sleep on amyloid β (Aβ) and tau dynamics, impaired proteostasis, along with appropriate measures to treat few contributing factors that lead to insomnia in AD or Mild Cognitive Impairment (MCI).
Export Options
About this article
Cite this article as:
Chauhan Singh Pallavi , Mishra Meerambika , Koul Bhupendra , Sharma Mayank and Yadav Dhananjay *, Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance, CNS & Neurological Disorders - Drug Targets 2021; 20 (7) . https://dx.doi.org/10.2174/1871527320666210319111852
DOI https://dx.doi.org/10.2174/1871527320666210319111852 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Lung Cancer Chemotherapy, New Treatment and Related Patents
Recent Patents on Anti-Cancer Drug Discovery Neurovirulence of SARS CoV2: From Clinical Data to Preclinical Neuropsychological Exploration
Coronaviruses Understanding the Use of Immunosuppressive Agents in the Clinical Management of IBD
Current Drug Targets Brain Perfusion In Sepsis
Current Vascular Pharmacology Combining Cytotoxic and Immune-Mediated Gene Therapy to Treat Brain Tumors
Current Topics in Medicinal Chemistry Perspectives in Genomics The Future of Fungi in ‘omics’ era
Current Genomics Inorganic-organic Nanomaterials for Therapeutics and Molecular Imaging Applications
Nanoscience & Nanotechnology-Asia The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets MicroRNAs and Stem Cells to the Rescue
Current Neurovascular Research 5-HT1 Receptors
Current Drug Targets - CNS & Neurological Disorders Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Responses of Glial Cells to Stress and Glucocorticoids
Current Immunology Reviews (Discontinued) Alternatives to Conventional Vaccines - Mediators of Innate Immunity
Current Drug Targets Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity
Current Immunology Reviews (Discontinued) Laccase Regulators in Anti-fungal Drug Discovery: Dark Lessons from the AIDS-related Pathogen, Cryptococcus
Current Enzyme Inhibition Mechanisms of Epileptiform Synchronization in Cortical Neuronal Networks
Current Medicinal Chemistry Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology